121 related articles for article (PubMed ID: 15784335)
1. Multivariate modeling of cytochrome P450 3A4 inhibition.
Kriegl JM; Eriksson L; Arnhold T; Beck B; Johansson E; Fox T
Eur J Pharm Sci; 2005 Apr; 24(5):451-63. PubMed ID: 15784335
[TBL] [Abstract][Full Text] [Related]
2. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.
Kriegl JM; Arnhold T; Beck B; Fox T
J Comput Aided Mol Des; 2005 Mar; 19(3):189-201. PubMed ID: 16059671
[TBL] [Abstract][Full Text] [Related]
3. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors.
Jensen BF; Vind C; Padkjaer SB; Brockhoff PB; Refsgaard HH
J Med Chem; 2007 Feb; 50(3):501-11. PubMed ID: 17266202
[TBL] [Abstract][Full Text] [Related]
4. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Roy K; Pratim Roy P
Eur J Med Chem; 2009 Jul; 44(7):2913-22. PubMed ID: 19128860
[TBL] [Abstract][Full Text] [Related]
5. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
[TBL] [Abstract][Full Text] [Related]
6. Classification models for CYP450 3A4 inhibitors and non-inhibitors.
Choi I; Kim SY; Kim H; Kang NS; Bae MA; Yoo SE; Jung J; No KT
Eur J Med Chem; 2009 Jun; 44(6):2354-60. PubMed ID: 19026469
[TBL] [Abstract][Full Text] [Related]
7. Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates.
Crivori P; Zamora I; Speed B; Orrenius C; Poggesi I
J Comput Aided Mol Des; 2004 Mar; 18(3):155-66. PubMed ID: 15368916
[TBL] [Abstract][Full Text] [Related]
8. Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.
Tie Y; McPhail B; Hong H; Pearce BA; Schnackenberg LK; Ge W; Buzatu DA; Wilkes JG; Fuscoe JC; Tong W; Fowler BA; Beger RD; Demchuk E
Molecules; 2012 Mar; 17(3):3407-60. PubMed ID: 22421793
[TBL] [Abstract][Full Text] [Related]
9. QSAR modeling of in vitro inhibition of cytochrome P450 3A4.
Mao B; Gozalbes R; Barbosa F; Migeon J; Merrick S; Kamm K; Wong E; Costales C; Shi W; Wu C; Froloff N
J Chem Inf Model; 2006; 46(5):2125-34. PubMed ID: 16995743
[TBL] [Abstract][Full Text] [Related]
10. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method.
Wanchana S; Yamashita F; Hashida M
Pharm Res; 2003 Sep; 20(9):1401-8. PubMed ID: 14567634
[TBL] [Abstract][Full Text] [Related]
11. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models.
Gleeson MP; Davis AM; Chohan KK; Paine SW; Boyer S; Gavaghan CL; Arnby CH; Kankkonen C; Albertson N
J Comput Aided Mol Des; 2007; 21(10-11):559-73. PubMed ID: 18034311
[TBL] [Abstract][Full Text] [Related]
12. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
Roy K; Roy PP
Eur J Med Chem; 2009 May; 44(5):1941-51. PubMed ID: 19110342
[TBL] [Abstract][Full Text] [Related]
13. The computational model to predict accurately inhibitory activity for inhibitors towards CYP3A4.
Xie Z; Zhang T; Wang JF; Chou KC; Wei DQ
Comput Biol Med; 2010; 40(11-12):845-52. PubMed ID: 20951982
[TBL] [Abstract][Full Text] [Related]
14. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4.
Ekins S; Berbaum J; Harrison RK
Drug Metab Dispos; 2003 Sep; 31(9):1077-80. PubMed ID: 12920160
[TBL] [Abstract][Full Text] [Related]
15. Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors.
Arimoto R; Prasad MA; Gifford EM
J Biomol Screen; 2005 Apr; 10(3):197-205. PubMed ID: 15809315
[TBL] [Abstract][Full Text] [Related]
16. Kohonen maps for prediction of binding to human cytochrome P450 3A4.
Balakin KV; Ekins S; Bugrim A; Ivanenkov YA; Korolev D; Nikolsky YV; Skorenko AV; Ivashchenko AA; Savchuk NP; Nikolskaya T
Drug Metab Dispos; 2004 Oct; 32(10):1183-9. PubMed ID: 15231683
[TBL] [Abstract][Full Text] [Related]
17. An Uncertainty-Guided Deep Learning Method Facilitates Rapid Screening of CYP3A4 Inhibitors.
Wang R; Liu Z; Gong J; Zhou Q; Guan X; Ge G
J Chem Inf Model; 2023 Dec; 63(24):7699-7710. PubMed ID: 38055780
[TBL] [Abstract][Full Text] [Related]
18. Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors.
Afzelius L; Masimirembwa CM; Karlén A; Andersson TB; Zamora I
J Comput Aided Mol Des; 2002 Jul; 16(7):443-58. PubMed ID: 12510879
[TBL] [Abstract][Full Text] [Related]
19. Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.
Zientek M; Stoner C; Ayscue R; Klug-McLeod J; Jiang Y; West M; Collins C; Ekins S
Chem Res Toxicol; 2010 Mar; 23(3):664-76. PubMed ID: 20151638
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
